NCT03197506: Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
- State
- Under way
- Phase
- Phase 2
- People
- 52 taking part
- Started
- 15 Jan 2018
- Primary completion
- 16 Jul 2024
- Arms
- Group 1 (pembrolizumab, surgery, temozolomide, radiation)
- Results
- Posted on the registry
- 23 Jun 2017: Trial registered
- 15 Jan 2018: Trial started
- 25 Mar 2026: Trial results posted
Posted results
The numbers the trial's sponsor posted to the registry, as written there. The registry record says what each measure runs from and to.
Incidence of Dose Limiting Toxicities
Primary outcome · Number of participants · 189 days
| Group | Analysed | Value |
|---|---|---|
| Group 1 Dose Level 1 Cohort 1 | 3 | 1 |
| Group 1 Dose Level 1 Cohort 2 | 3 | 1 |
| Group 1 Dose Level 1 Cohort 3 | 3 | 0 |
| Group 1 Dose Level 1 Cohort 4 | 3 | 1 |
Group 2 Overall Survival (OS) at 18 Months
Primary outcome · Number of participants · 18 months
| Group | Analysed | Value |
|---|---|---|
| Group 2 | 33 | 19 |
Incidence of Adverse Events
Secondary outcome · Number of participants · 14 months
| Group | Analysed | Value |
|---|---|---|
| Group 1 | 15 | 6 |
| Group 2 | 36 | 18 |
Time Until Treatment Related Grade 3+ Adverse Event
Secondary outcome · Median, Months · 14 months
| Group | Analysed | Value |
|---|---|---|
| Group 1 | 15 | NA (95% Confidence Interval 3.7 to NA) |
| Group 2 | 36 | 6.9 (95% Confidence Interval 4.7 to NA) |
Time to Progression (Group 2)
Secondary outcome · Median, Months · 36 months
| Group | Analysed | Value |
|---|---|---|
| Group 2 | 36 | 10.7 (95% Confidence Interval 8.0 to 12.2) |
Progression-free Survival (Group 2)
Secondary outcome · Median, Months · 36 months
| Group | Analysed | Value |
|---|---|---|
| Group 2 | 36 | 10.7 (95% Confidence Interval 8.0 to 12.2) |
Time to Treatment Failure (Group 2)
Secondary outcome · Median, Months · 13 months
| Group | Analysed | Value |
|---|---|---|
| Group 2 | 36 | 8.3 (95% Confidence Interval 6.1 to 10.9) |